ARGX 115

Drug Profile

ARGX 115

Alternative Names: ARGX-115

Latest Information Update: 18 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Catholic University of Louvain; Ludwig Institute for Cancer Research
  • Developer argenx; Catholic University of Louvain
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Transforming growth factor beta1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 13 Apr 2017 argenx announces intention to file an IND application for ARGX 115
  • 21 Apr 2016 arGEN-X and Abbvie agree to co-develop and co-commercialise ARGX 115 for Cancer
  • 13 Oct 2015 ArGEN-X excerised option to license ARGX 115
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top